drugset / Trial / NCT04984733
Temozolomide + Nivolumab in MGMT Methylated Oesophagogastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
An open label single arm phase II trial in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma which is MGMT deficient.
Timeline
- Start
- 2021-09-28
- Primary completion
- 2024-10-23
- Completion
- 2024-10-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | 240 mg | Intravenous |
| Subject | Temozolomide | Small molecule | 50 mg/m2 | Oral |